SR (SR)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 6/9, Altman Z 0.7.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe capital efficiency profile reveals a significant divergence between return on invested capital and shareholder equity returns, driven primarily by leverage rather than operational momentum. While the 11% net margin suggests pricing power or cost discipline, the ROIC of just 4.7% indicates that core business generation struggles to cover the weighted average cost of capital without financial engineering; this is confirmed by a DuPont decomposition where an equity multiplier of 3.42x artificially inflates the 8% return on equity despite low asset turnover at only 0.21x. Credit quality metrics present a mixed signal: the Beneish M-Score of -2.54 points to strong earnings authenticity, yet a Piotroski F-Score of 6/9 reflects moderate fundamental stability that lacks the robustness of high-quality compounders, especially in the context of negative revenue growth of 4.5% year-over-year which erodes top-line momentum despite healthy gross margins expanding to 41.5%.
Valuation metrics currently trade at a premium relative to deteriorating fundamentals and historical norms, creating a potential value trap scenario. The current price-to-earnings ratio of 19.8x implies that the market is pricing in sustained future growth or exceptional risk-adjusted returns that are not supported by the observed contraction in revenue; without specific sector benchmarks provided to normalize this multiple, it appears elevated given the negative earnings trajectory and sub-par ROIC generation. A standard discounted cash flow analysis would likely challenge these assumptions, as implied growth rates required to justify a nearly 20x multiple on shrinking top-line performance seem inconsistent with the company's current operational headwinds and inefficient capital deployment relative to its cost of equity.
Risk assessment highlights a precarious balance between earnings integrity and business sustainability. While insider activity remains neutral over the last ninety days, offering no clear directional signal from management regarding strategic pivots or distress, the combination of declining revenue and low asset turnover suggests structural inefficiencies that may persist regardless of leverage adjustments. The Fama-French alpha data is unavailable in the provided dataset, preventing a definitive assessment of whether the stock has outperformed based on size, value, or momentum factors historically; however, the reliance on high financial leverage to achieve an 8% ROE while generating only 4.7% pre-leverage returns exposes significant downside volatility if credit conditions tighten or asset turnover fails to improve.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like VPU or SDY, the fund manager is mechanically forced to buy or sell SR shares regardless of SR's individual fundamentals. We estimate $332M of passive capital is structurally linked to SR through 8 tracked ETFs. Passive flows have a limited but growing influence on SR's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in SR to visualize passive redemption contagion across ETFs and collateral stocks.
If SR (SR) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies NextEra Energy Inc. (NEE) as the most exposed collateral stock, sharing 1 ETFs with SR. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 11 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
SR Ownership Dynamics
ETFs with Highest SR Exposure
Float lock-up computed from 11 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
SR Capital Efficiency
How efficiently does SR convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
SR converts -41% of its EBITDA into free cash flow, negative FCF conversion — the company is consuming cash faster than it generates EBITDA, which is unsustainable long-term. The 141% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-2.2%), suggesting reinvested capital is destroying shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-11 | 3,330 | $85.70 | $285,381 |
| 2026-05-06 | 33 | $89.81 | $2,963.73 |
| 2026-05-04 | 32 | $90.41 | $2,893.12 |
| 2026-04-24 | 5 | $91.31 | $456.55 |
| 2026-04-21 | 174 | $91.54 | $15,927.96 |
| 2026-03-31 | 825 | $91.40 | $75,405 |
| 2026-03-30 | 37 | $90.68 | $3,355.16 |
| 2026-03-26 | 2,264 | $90.24 | $204,303.36 |
| 2026-03-18 | 300 | $91.87 | $27,561 |
| 2026-03-12 | 33 | $89.96 | $2,968.68 |
| 2026-03-06 | 249 | $91.01 | $22,661.49 |
| 2026-02-27 | 630 | $90.80 | $57,204 |
| 2026-02-02 | 72 | $84.49 | $6,083.28 |
| 2026-01-30 | 50 | $84.86 | $4,243 |
| 2026-01-27 | 40,255 | $84.06 | $3.4M |
| 2026-01-23 | 55 | $84.05 | $4,622.75 |
| 2026-01-21 | 42,090 | $83.59 | $3.5M |
| 2026-01-20 | 7 | $83.54 | $584.78 |
| 2026-01-14 | 24,300 | $81.54 | $2.0M |
| 2026-01-07 | 21 | $81.98 | $1,721.58 |
| 2025-12-29 | 121 | $82.97 | $10,039.37 |
| 2025-12-23 | 312 | $82.77 | $25,824.24 |
| 2025-12-12 | 2,031 | $82.13 | $166,806.03 |
| 2025-11-24 | 256 | $86.10 | $22,041.6 |
| 2025-11-17 | 40 | $87.00 | $3,480 |
| 2025-10-31 | 184 | $87.48 | $16,096.32 |
| 2025-10-22 | 809 | $86.87 | $70,277.83 |
| 2025-10-16 | 2 | $85.48 | $170.96 |
| 2025-10-10 | 39 | $83.19 | $3,244.41 |
| 2025-10-08 | 1 | $83.02 | $83.02 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare SR to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.